ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -18 مورد

Risk factors for immune checkpoint inhibitor pneumonitis

Risk factors for immune checkpoint inhibitor pneumonitis
Type of malignancy
  • Non-small cell lung cancer (squamous cell carcinoma at higher risk than non-squamous cell carcinoma of the lung)
  • Renal cell carcinoma
ICI regimen
  • Combination immunotherapy (eg, CTLA-4 inhibitor plus PD-L1 inhibitor) carries a higher risk than single-agent immunotherapy (eg, PD-1 or PD-L1 inhibitors)
Pre-existing interstitial lung abnormality or confirmed interstitial lung disease
Chronic lung disease (eg, chronic obstructive pulmonary disease, asthma)
Smoking or tobacco use
Autoimmune disease
Prior curative-intent radiation therapy to the lungs
Male sex
CTLA-4: cytotoxic T lymphocyte-associated antigen 4; ICI: immune checkpoint inhibitor; PD-1: programmed cell death receptor 1; PD-L1: programmed cell death ligand 1.
References:
  1. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017; 10:50.
  2. Tiu BC, Zubiri L, Iheke J, et al. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: A multi-institutional cohort study. J Immunother Cancer 2022; 10:e00460.
  3. Atchley W, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: Real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest 2021; 160:731.
Graphic 145876 Version 1.0